Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma

by Accardi, F., Anderson, K.C, Bae, J., Hideshima, T., Munshi, N.C, Prabhala, R., Richardson, P.G, Rowell, S., Shambley, A., Tai, Y.-T, Wen, K.
Published 2022

Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes

by Carlo-Stella, C., Carreras, E., Castro, P., Díaz-Ricart, M., Escolar, G., Fernández, S., García-Bernal, D., Martinez-Sanchez, J., Moraleda, J.M, Moreno-Castaño, A.B, Nicolás, J.M, Palomo, M., Richardson, E., Richardson, P.G, Seguí, F., Téllez, A., Torramadé-Moix, S., Ventosa, H.
Published 2022

Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

by Alegre, A., Bakker, N.A, Bladé, J., Cavo, M., Larocca, A., Laubach, J., Leleu, X., Maisel, C., Mateos, M.-V, Mazumder, A., Nadeem, O., Oriol, A., Orre, M., Paner, A., Raptis, A., Richardson, P.G, Rodriguez-Otero, P., Sandberg, A., Torrång, A., Touzeau, C.
Published 2022

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

by Anderson, L.D., Jr, Beksac, M., Corso, A., Dimopoulos, M., Dürig, J., Engelhardt, M., Galli, M., Grote, L., Jenner, M., Jiang, R., Kanate, A.S, Larocca, A., Liberati, A.M, Lindsay, J., Moreau, P., Oriol, A., Pavic, M., Peluso, T., Richardson, P.G, Robak, P., Rodriguez-Otero, P., Salomo, M., Schjesvold, F., Sonneveld, P., Vural, F., Weisel, K., White, D., Yagci, M.
Published 2022